Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Category: Uncategorized

Bronchogen

Our opinion on this compoundSingle-lab provenance

35/100

Interesting epigenetic mechanism claim anchored to single-consortium preclinical work with zero human trial data

Look, Bronchogen sits in a category that demands honest scrutiny: the Khavinson ultrashort peptide family, where the evidence has a consistent structural problem. The Saint Petersburg Institute of Bioregulation and Gerontology has produced decades of work on tissue-specific tetrapeptides, and Bronchogen (ADEL; H-Ala-Asp-Glu-Leu-OH) is their bronchopulmonary entry. The mechanism story is genuinely interesting on paper. Direct peptide-DNA binding leading to chromatin remodeling and reactivation of transcriptional programs in bronchial epithelial cells is not a boring claim. Ki67 upregulation, Mcl-1 regulation, NOS-3 modulation, ciliated epithelial restoration in nitrogen dioxide-induced COPD rat models — the preclinical data is internally consistent and mechanistically coherent.

Here’s the thing, though: all of this comes from essentially one research consortium. Khavinson’s lab is both the discoverer and the sole replicator. That’s the same situation as Epitalon, Cardiogen, Cortagen, and the rest of the family. The epigenetic DNA-binding mechanism is compelling as a hypothesis but has not been independently validated outside that group. When a single institution controls both the original characterization and all subsequent replication, the evidence quality ceiling drops sharply regardless of how interesting the proposed biology is.

The differentiation picture is also weaker than it looks. Bronchogen shares the bronchopulmonary tissue-specificity claim with Chonluten (EDL tripeptide), which is the shorter sibling from the same lab. Two Khavinson bronchopulmonary peptides with overlapping claimed activities, both from a single source, neither with external replication — thats not head-to-head competition, that’s a redundancy problem. Against the broader respiratory-protective compound space, BPC-157 and GHK-Cu have multi-lab preclinical coverage, and NAC has decades of real clinical evidence in COPD. Bronchogen has none of that external support.

There is no published human clinical trial data. Zero. The Russian BAA registration represents dietary supplement classification, not clinical proof of efficacy. Pharmacokinetic data on the isolated synthetic ADEL tetrapeptide is absent; the PEPT1/PEPT2 intestinal transport hypothesis is reasonable for tetrapeptides as a class but has not been demonstrated specifically for this compound. Oral bioavailability is assumed rather than measured.

We think the epigenetic chromatin remodeling angle for ultrashort peptides is worth watching. If independent groups ever validate the Khavinson DNA-binding model, the whole family including Bronchogen gets significantly more interesting as a research tool. Right now, that validation hasnt happened. For an investigator working on bronchial epithelial biology or COPD models, Bronchogen is a plausible probe for a specific hypothesis, but you’re building on a literature base that hasn’t cleared the replication hurdle. That constraint is what keeps the score where it is.

Novelty

48

Mechanism promise

50

In-category differentiation

30

Evidence quality

22

Translational signal

20

Research bench value

30

Rationale Bronchogen shares the structural evidence problem of the entire Khavinson family: the Saint Petersburg Institute is both originator and sole replicator, producing an internally consistent but externally unvalidated literature. The DNA-chromatin remodeling mechanism is a genuinely interesting hypothesis, but no independent lab has confirmed it and no human clinical data exists, placing it firmly alongside Epitalon in the single-lab-only tier.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic bronchopulmonary tetrapeptide bioregulator with epigenetic gene-regulatory and anti-inflammatory activity targeting bronchial epithelium

A synthetic tetrapeptide (H-Ala-Asp-Glu-Leu-OH; ADEL) developed at the Saint Petersburg Institute of Bioregulation and Gerontology as an ultrashort peptide bioregulator with bronchopulmonary tissue-specific proliferative, anti-inflammatory, and epithelial-regenerative activity targeting bronchial epithelium, ciliated cell restoration, and respiratory mucosal barrier function.

Abstract

Bronchogen (H-Ala-Asp-Glu-Leu-OH; ADEL tetrapeptide; molecular formula C18H30N4O9; molecular weight 446.45 g/mol) is a synthetic tetrapeptide bioregulator developed by Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology as the bronchopulmonary-specific member of the Khavinson ultrashort peptide bioregulator family [1, 2]. The compound belongs to a class of synthetic two-to-seven-residue peptide sequences modeled on tissue-specific peptide fragments isolated from mammalian organ extracts, and is designated as the respiratory system bioregulator within this peptide family. Bronchogen is structurally related to but distinct from the other Khavinson tetrapeptides that share the Ala-Glu-Asp tripeptide core (Cardiogen, Cortagen, Epithalon); the ADEL sequence carries a different arrangement of the acidic residues (Asp at position two, Glu at position three) and a hydrophobic leucine residue at the C-terminus, a configuration that determines bronchial tissue specificity within the Khavinson classification system [3, 4]. The principal molecular mechanism of Bronchogen, characterized through molecular modeling, cell culture, organotypic bronchial tissue studies, and animal models of obstructive lung disease, is epigenetic regulation of gene expression through direct interaction of the tetrapeptide with double-stranded DNA and with histone proteins, producing chromatin remodeling and reactivation of transcriptional programs in bronchial epithelial cells [5, 6, 7]. The bronchopulmonary activity, characterized in organotypic lung tissue cultures from young and aged rats, human bronchial epithelial cell cultures across multiple passages, and nitrogen dioxide-induced chronic obstructive pulmonary disease (COPD) rat models, includes stimulation of bronchial epithelial cell proliferation and differentiation with upregulation of differentiation markers in aging cell cultures [8, 9], regulation of Ki67, Mcl-1, p53, CD79, and endothelial nitric oxide synthase (NOS-3) protein expression in human bronchial epithelium [5], restoration of normal ciliated epithelial architecture with reduction of goblet cell hyperplasia and squamous metaplasia in COPD models [10], normalization of proinflammatory cytokine profiles and neutrophilic inflammation in bronchoalveolar lavage fluid [10, 11], and enhancement of secretory immunoglobulin A and surfactant protein B production indicating recovery of respiratory mucosal barrier and surfactant function [11]. No formal pharmacokinetic studies have been published for Bronchogen as the isolated synthetic ADEL tetrapeptide. As a linear tetrapeptide with unprotected termini, the compound is expected to undergo rapid proteolytic degradation by aminopeptidases and carboxypeptidases in plasma and gastrointestinal fluid; however, molecular modeling studies have demonstrated that ultrashort peptides are substrates of the proton-coupled oligopeptide transporter (PEPT1/PEPT2) family carriers, supporting intestinal absorption and cellular uptake through active transport mechanisms [12, 13]. No human clinical trials have been published. The compound is not approved by the United States Food and Drug Administration, the European Medicines Agency, or any major Western regulatory authority. Bronchogen is registered in the Russian Federation as a biologically active additive and is commercially available there in capsule formulations. It is supplied internationally as a research-grade lyophilized peptide by multiple peptide synthesis vendors at greater than 95 percent purity by high-performance liquid chromatography. This monograph reviews the chemistry, synthesis, and structural characterization of Bronchogen; the discovery and development history within the Khavinson bioregulatory peptide program; the molecular pharmacology including peptide-DNA binding, histone interaction, and bronchial gene expression modulation; the pharmacokinetic considerations for ultrashort peptides; the preclinical pharmacology across bronchial, inflammatory, and aging cell models; the clinical evidence base (absent); sourcing and quality verification; reconstitution and handling; stack interactions and combinations; adverse events and safety signal; and a comparative assessment of five bronchopulmonary or respiratory-protective peptide candidates (Chonluten, GHK-Cu, BPC-157, Thymalin, N-acetylcysteine) against Bronchogen on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1511Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
Glutathione

Our opinion on this compoundResearch workhorse

33/100

Century-old redox infrastructure molecule; thoroughly characterized, poor exogenous pharmacology, real bench utility

Look, glutathione is one of the most important molecules in mammalian biology. That’s also exactly why it scores low here. When a compound’s mechanism fills entire textbook chapters and has been understood for decades, it’s not a research frontier. It’s infrastructure. Hopkins pulled it from yeast and blood in 1921. The gamma-glutamyl linkage was elucidated through the 1930s. The GPx, GST, and glutaredoxin frameworks were mapped systematically across the 1970s and 80s. The Nrf2-Keap1 regulatory axis that governs endogenous GSH synthesis is now itself a drug target with its own crowded literature. There’s not much left to discover about what glutathione does. That’s the honest position.

The bench value is what keeps this off the floor. The GSH/GSSG redox couple is a workhorse readout in any lab doing oxidative stress biology. Ellman’s reagent, HPLC quantification of thiol pools, fluorescent roGFP reporters: these are standard assays that make glutathione genuinely useful as a reference substrate and redox indicator. If you’re studying Nrf2 pathway modulation, or comparing antioxidant interventions in a hepatocyte model, GSH/GSSG ratios are central. That’s real bench utility, and we credit it accordingly.

But as a research target (as the compound you’d anchor a funded investigation around) the case is weak. The mechanism is solved. Differentiation is poor: NAC consistently outperforms direct GSH supplementation for raising intracellular thiol pools, because oral glutathione is hydrolyzed in the gut before meaningful absorption and the body regulates its own biosynthesis tightly through gamma-glutamylcysteine synthetase. There is literature on liposomal forms and S-acetyl-glutathione improving cellular delivery, but those are derivatives with their own research profiles; plain GSH gets credit for none of that here.

The clinical picture is scattered. Small trials span Parkinson’s disease, NAFLD, COPD, type 2 diabetes, and skin lightening. Some signals are real but modest and inconsistently replicated. None rise to the level of a compelling, replicated human outcome that would anchor a program. The IV use in acetaminophen hepatotoxicity is clinically valid, but NAC owns that indication and has for thirty years.

What we like: the bench utility in redox biology is genuine and not going away. What we don’t like: brilliant molecule, largely solved biology, poor exogenous pharmacology, no defining clinical signal, and multiple better alternatives for almost every application someone might cite. Thats the summary. We use it in assays. We dont build research programs around it.

Novelty

14

Mechanism promise

18

In-category differentiation

25

Evidence quality

55

Translational signal

45

Research bench value

62

Rationale Novelty and mechanism scores bottom out because glutathione’s biochemistry is textbook-complete across a century of literature; the compound earns a moderate bench_value credit for its indispensable role as a redox assay reference, but that is insufficient to offset near-zero novelty and weak differentiation against precursors like NAC.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous tripeptide thiol antioxidant and phase II conjugation cofactor

The principal low-molecular-weight thiol in mammalian cells, serving as the dominant intracellular antioxidant, electrophile conjugation substrate, and redox signaling mediator across virtually all aerobic tissues.

Abstract

Glutathione (gamma-L-glutamyl-L-cysteinyl-glycine; GSH) is a ubiquitous tripeptide thiol present in virtually all mammalian cells at intracellular concentrations of 1 to 10 millimolar, constituting the single most abundant non-protein sulfhydryl compound in animal tissues and the central node of cellular redox homeostasis. First isolated by Sir Frederick Gowland Hopkins in 1921 from yeast, blood, and muscle tissue and subsequently characterized as a gamma-linked glutamyl-cysteinyl-glycine tripeptide by Hopkins and colleagues over the following decade, glutathione occupies a singular position in biochemistry: it is simultaneously the principal intracellular reductant maintaining the thiol-disulfide balance of cytosolic and mitochondrial protein pools; the obligate cofactor for glutathione peroxidases (GPx1 through GPx8), glutathione S-transferases (GST alpha, mu, pi, theta, sigma, kappa, omega, and zeta classes), and glutaredoxins; and the substrate for phase II xenobiotic conjugation reactions that render electrophilic metabolites water-soluble for biliary and renal excretion. The reduced form (GSH) predominates under physiological conditions, typically exceeding the oxidized disulfide form (GSSG) by a ratio of 100:1 in the cytosol, with the GSH/GSSG redox couple establishing the electrochemical set point against which cellular redox-sensitive signaling cascades operate, including nuclear factor erythroid 2-related factor 2 (Nrf2) activation, NF-kappaB modulation, and apoptosis signal-regulating kinase 1 (ASK1) regulation.

Biosynthesis proceeds through two sequential ATP-dependent enzymatic steps: gamma-glutamylcysteine ligase (GCL, formerly gamma-glutamylcysteine synthetase) catalyzes the rate-limiting condensation of L-glutamate and L-cysteine via an atypical gamma-carboxyl peptide bond, and glutathione synthetase (GSS) subsequently ligates glycine to the gamma-glutamylcysteine dipeptide. Both enzymes are transcriptionally regulated by the Nrf2-Keap1-ARE (antioxidant response element) pathway, establishing a feedback loop in which oxidative or electrophilic stress induces Nrf2 nuclear translocation, upregulates GCL and GSS expression, and thereby increases glutathione synthesis capacity. Cysteine availability is typically the rate-limiting substrate for biosynthesis, a constraint that underwrites the therapeutic rationale for N-acetylcysteine (NAC) as an indirect glutathione precursor strategy.

The pharmacokinetics of exogenous glutathione are dominated by poor oral bioavailability. The intact tripeptide is a substrate for gamma-glutamyltransferase (GGT) at the intestinal brush border and for intraluminal peptidases, resulting in extensive presystemic hydrolysis. Early pharmacokinetic studies in humans reported negligible increases in plasma or erythrocyte glutathione after single oral doses of reduced glutathione. However, a landmark 2015 randomized, double-blind, placebo-controlled trial by Richie et al. demonstrated that chronic oral supplementation at 250 mg or 1,000 mg daily for six months produced significant, dose-dependent increases in glutathione stores in erythrocytes (up to 35 percent), plasma, lymphocytes, and buccal mucosal cells, with an associated twofold increase in natural killer cell cytotoxicity in the high-dose group. These findings, together with subsequent work on liposomal, sublingual, and S-acetyl glutathione delivery systems that partially circumvent presystemic hydrolysis, have rekindled interest in direct glutathione supplementation as a complement to the established precursor strategy.

Clinically, glutathione depletion has been documented in a broad spectrum of disease states characterized by chronic oxidative stress, including Parkinson disease (40 percent depletion in the substantia nigra at preclinical stages), nonalcoholic fatty liver disease, chronic obstructive pulmonary disease, HIV/AIDS, cystic fibrosis, and age-related decline. Interventional evidence remains modest relative to the scope of the preclinical and epidemiological literature. In Parkinson disease, the Sechi et al. (1996) open-label study of intravenous glutathione (600 mg twice daily for 30 days) reported a 42 percent mean improvement in disability scores with effect persisting 2 to 4 months, but the Hauser et al. (2009) randomized, double-blind pilot trial of intravenous glutathione (1,400 mg three times weekly for 4 weeks) did not achieve statistical significance on the primary UPDRS endpoint, though a trend toward symptomatic improvement was noted. In hepatic applications, intravenous glutathione is used clinically in several jurisdictions as adjunctive therapy for drug-induced liver injury and for the potentiation of NAC in acetaminophen toxicity, where the glutathione-NAPQI conjugation pathway is the principal detoxification mechanism. In dermatology, oral and intravenous glutathione have been studied for skin lightening through inhibition of tyrosinase and melanin biosynthesis, with modest clinical evidence supporting efficacy at doses of 250 to 500 mg daily.

This monograph reviews the chemistry, biosynthesis, and compartmental distribution of glutathione; the enzymatic mechanisms of the glutathione-dependent antioxidant and conjugation systems; the pharmacokinetics and bioavailability considerations across oral, intravenous, liposomal, and sublingual routes; the preclinical pharmacology in models of neurodegeneration, hepatotoxicity, and inflammation; the clinical evidence base across neurological, hepatic, immunological, and dermatological indications; sourcing and quality verification considerations for research applications; reconstitution and handling; stack interactions with other redox-active compounds and pharmaceuticals; an adverse-event and safety profile; and a comparative assessment of five alternative glutathione-elevating strategies (N-acetylcysteine, S-acetyl-L-glutathione, liposomal glutathione, alpha-lipoic acid, and whey protein isolate) against reduced glutathione on five competency standards (bioavailability, effect size on tissue glutathione stores, clinical evidence breadth, side-effect profile, and overall validation).

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1517Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
Masteron

Our opinion on this compoundEstablished workhorse

25/100

Historically approved DHT-derived AAS displaced by superior agents, offering minimal modern research priority

Look, Masteron is one of those compounds where the story is almost entirely historical. Drostanolone propionate was synthesized at Syntex in 1959, got FDA approval for palliative breast cancer treatment in 1961, and spent roughly two decades as a legitimate oncology agent before tamoxifen made it essentially redundant. Thats the arc in a sentence.

The chemistry is genuinely interesting from a structure-activity standpoint and we want to be fair to it. The 2-alpha-methyl substitution on the DHT backbone confers resistance to 3-alpha-hydroxysteroid dehydrogenase metabolism in skeletal muscle, which is why drostanolone retains measurable anabolic activity where unmodified DHT is rapidly inactivated. The compound also cant be aromatized, so you get clean AR agonism without estrogenic conversion, which was actually the pharmacologically relevant feature for estrogen-sensitive postmenopausal mammary carcinoma. That’s an elegant exploitation of a known metabolic vulnerability. The problem is that elegant and novel are not the same thing. This mechanism has been picked apart for 65 years. There is nothing left to discover about how drostanolone binds AR.

The evidence base for the registered indication is real but dated in ways that matter. The breast cancer trials from the late 1960s and early 1970s were small by modern standards, variably blinded, and used response criteria that don’t map to contemporary oncology endpoints. The compound worked in context. But that clinical chapter closed decisively when SERMs and aromatase inhibitors arrived, and there is no active development program in any indication today. What remains in the literature are observational studies, narrow androgen physiology investigations, and performance-context reports that don’t constitute translatable bench research.

As an AR agonist probe, testosterone and DHT are more accessible reference compounds with deeper characterization literature. If selective AR modulation with tissue specificity is the question, the SARM literature has structurally and pharmacologically surpassed anything a 1959 androstane derivative can offer. The differentiation case for drostanolone in a modern research program depends entirely on the 3-alpha-HSD resistance story, which is pharmacologically legitimate but not under active investigation anywhere serious we can identify.

Scheduling is worth noting: drostanolone is Schedule III in the United States under the Anabolic Steroid Control Act. That adds real regulatory friction to a research protocol without any offsetting scientific upside. Hepatotoxicity is minimal relative to 17-alpha-alkylated AAS given the absence of that modification, but the scheduling status imposes compliance overhead that has to be weighed against what you’re actually going to learn. Honestly, the answer here is: not much that isn’t already known. Worth understanding for DHT analog SAR context, not a priority for active research time in 2026.

Novelty

15

Mechanism promise

22

In-category differentiation

28

Evidence quality

42

Translational signal

22

Research bench value

28

Rationale Drostanolone is a 65-year-old androstane steroid whose only registered indication was rendered obsolete by tamoxifen and aromatase inhibitors; the structural features are pharmacologically coherent but exhaustively characterized, and there is no active development program or emerging indication to drive research interest in 2026. Schedule III cap (75) does not bind since raw score falls well below it.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic anabolic-androgenic steroid; 2-alpha-methyl-5-alpha-dihydrotestosterone 17-beta-propionate ester (androstane-derived androgen receptor agonist)

A non-aromatizable, DHT-derived androgen receptor agonist originally developed by Syntex and approved for palliative treatment of advanced breast cancer in postmenopausal women, distinguished from other anabolic-androgenic steroids by its 2-alpha-methyl substitution conferring resistance to 3-alpha-hydroxysteroid dehydrogenase metabolism and a favorable anabolic-to-androgenic activity ratio.

Abstract

Masteron is the principal trade name for drostanolone propionate, the 17-beta-propionate ester of 2-alpha-methyl-5-alpha-dihydrotestosterone (2-alpha-methyl-DHT), a synthetic androstane steroid first described in 1959 and introduced to clinical medicine in 1961 following United States Food and Drug Administration approval for the palliative treatment of advanced, inoperable, androgen-responsive mammary carcinoma in postmenopausal women. The compound was developed by Syntex Corporation, licensed to Eli Lilly and Company, and marketed in the United States as Drolban and in European and other international markets as Masteril, Masteron, and Permastril. Drostanolone is a direct structural derivative of dihydrotestosterone (DHT) bearing a methyl group at the carbon-2 alpha position, a modification that confers two pharmacologically consequential properties: resistance to metabolic inactivation by 3-alpha-hydroxysteroid dehydrogenase (3-alpha-HSD) in skeletal muscle tissue, resulting in enhanced anabolic potency relative to the parent DHT molecule; and retention of the intrinsic non-aromatizability of the 5-alpha-reduced steroid nucleus, ensuring that the compound cannot be converted to estrogenic metabolites by the aromatase enzyme complex. As an androgen receptor (AR) agonist, drostanolone binds the AR with high affinity and initiates the canonical genomic androgen signaling cascade, including nuclear translocation, receptor dimerization, coactivator recruitment, and transcriptional activation of androgen-responsive genes governing protein synthesis, nitrogen retention, and musculoskeletal anabolism.

The clinical pharmacology of drostanolone propionate is defined by its intramuscular depot formulation. The propionate ester is hydrolyzed in vivo by tissue and plasma esterases to release the active drostanolone moiety, with an elimination half-life of approximately 2 to 3 days following intramuscular injection. The compound is not orally bioavailable owing to the absence of a 17-alpha-alkyl group; this same structural feature eliminates the hepatotoxicity risk associated with oral anabolic-androgenic steroids such as methyltestosterone and oxymetholone. Protein binding is high, predominantly to sex hormone-binding globulin (SHBG) and albumin. Metabolism proceeds through reduction and conjugation pathways; the principal urinary metabolites include 2-alpha-methyl-5-alpha-androstan-3-alpha-ol-17-one and its glucuronide and sulfate conjugates, which serve as the analytical targets for anti-doping detection.

The registered clinical indication was the palliation of advanced breast cancer in women who were more than one year but less than five years postmenopausal, with documented androgen-responsive or estrogen-receptor-positive disease that had progressed following initial endocrine therapies. Early clinical trials reported objective response rates of approximately 20 to 30 percent, including partial tumor regression and symptomatic palliation. The antitumor mechanism was attributed to competitive androgen receptor-mediated antagonism of estrogen-dependent tumor proliferation, with additional evidence suggesting inhibition of prolactin receptor expression and downregulation of estrogen receptor density in mammary tissue. The clinical application of drostanolone propionate and other androgenic agents in breast cancer was largely superseded in the 1970s and 1980s by the introduction of selective estrogen receptor modulators (tamoxifen) and subsequently by aromatase inhibitors (anastrozole, letrozole, exemestane), which offered comparable or superior efficacy with substantially reduced virilization burden. Drostanolone propionate is no longer marketed in any jurisdiction for the breast cancer indication.

The compound persists in contemporary relevance principally through its widespread non-medical use in performance and physique enhancement contexts, where it is valued for its non-aromatizable androgenic profile, its favorable anabolic-to-androgenic ratio, and its relatively mild side-effect burden compared to other injectable anabolic-androgenic steroids. Drostanolone is classified as a prohibited substance by the World Anti-Doping Agency (WADA) under the category of anabolic agents (S1) and is detectable in urine for up to 3 to 4 weeks following administration through gas chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry analysis of phase II metabolite conjugates. This monograph reviews the chemistry, synthesis, and stereochemistry of drostanolone propionate; the androgen receptor-mediated mechanism of action including antiestrogenic activity in mammary tissue; the pharmacokinetic profile of the propionate and enanthate ester formulations; the preclinical pharmacology; the clinical evidence base in breast cancer and related indications; sourcing and quality verification considerations; reconstitution and handling; stack interactions with other androgenic and ancillary compounds; adverse events and safety signals; and a comparative assessment of five alternative androgenic or antiestrogenic agents against drostanolone propionate on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1550Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
PPAP-HCl

Our opinion on this compoundNiche research probe

45/100

Niche Knoll-school catecholaminergic probe with fresh TAAR1 data but thin independent replication

PPAP-HCl sits in an unusual corner of catecholaminergic pharmacology, which is exactly what makes it interesting to a small but serious group of investigators. Jozsef Knoll’s group at Semmelweis synthesized this compound in the late 1980s as a deliberate surgical operation on selegiline: keep the catecholaminergic enhancer activity, strip the MAO-B inhibition. The idea was to isolate what Knoll called the enhancer effect from the messier polypharmacology of the parent compound, and they largely succeeded.

What we find genuinely compelling here is the mechanism story, which has gotten more interesting with time rather than less. The original catecholaminergic activity enhancer concept, potentiating impulse-dependent dopamine and norepinephrine release from vesicles without triggering the uncontrolled efflux characteristic of amphetamine, was already novel when Knoll formally described it in 1992. The compound doesn’t block autoreceptors, doesn’t inhibit MAO, and doesn’t operate like a classical reuptake inhibitor. It was a genuinely different way of thinking about catecholaminergic modulation, and that distinctiveness still holds up.

The 2025 pharmacological characterization adds another layer worth paying attention to. PPAP turns out to be a potent DAT reuptake inhibitor at an IC50 of 57.5 nM and a NET inhibitor at 571 nM, which means the pure-enhancer framing from the original Knoll papers was incomplete. Now you have a compound with dual mechanism: enhancer activity plus reuptake inhibition, and putative TAAR1 agonism as a possible mechanistic spine for both. TAAR1 is a genuinely active research area right now, and PPAP offers investigators a structurally distinct probe that differs from the typical TAAR1 ligands in the literature. Thats a real asset for anyone trying to dissect the receptor’s role in impulse-dependent dopamine dynamics.

Here’s where we have to be honest about the limitations. The evidence base is thin in a specific way: it’s not that there are no data, it’s that Knoll’s Semmelweis group generated most of it across a publishing window that closed around 2005. Meaningful independent replication is limited. There are no human clinical trials to speak of. PPAP has never moved through the clinic, and without a bench-to-human arrow it’s hard to know what effect size actually looks like in people. The 2025 DAT/NET characterization comes from outside Semmelweis, which helps, but one fresh paper doesn’t change the structural evidence problem.

We think this compound has real utility as a research tool for anyone working on TAAR1 biology or the CAE mechanism specifically. It’s a structurally clean, chirally defined probe with a long preclinical track record and a freshly updated mechanistic profile. For that specific research context it earns shelf space. But it’s not a compound with broad crossover appeal, and the evidence base doesn’t justify treating it as anything beyond a niche investigational tool at this stage.

Novelty

48

Mechanism promise

65

In-category differentiation

48

Evidence quality

28

Translational signal

18

Research bench value

55

Rationale Evidence base is primarily the Knoll group at Semmelweis across a 15-20 year window now mostly closed, with no independent clinical development; the dual CAE-plus-DAT-inhibition mechanism and 2025 TAAR1 characterization give it genuine bench value in catecholaminergic research, but evidence quality and a complete absence of human data drag the overall down significantly.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Catecholaminergic activity enhancer (CAE) and dopamine transporter reuptake inhibitor derived from the phenylalkylamine/substituted amphetamine scaffold

A selegiline-derived catecholaminergic activity enhancer that potentiates impulse-dependent dopamine and norepinephrine release in the brain without monoamine oxidase inhibition, distinguished from classical psychostimulants by a broad therapeutic dose window and absence of uncontrolled monoamine efflux.

Abstract

PPAP-HCl, the hydrochloride salt of (-)-(R)-1-phenyl-2-propylaminopentane, is an experimental catecholaminergic activity enhancer (CAE) compound originally synthesized by Jozsef Knoll and colleagues at Semmelweis University in Budapest in the late 1980s as a structural derivative of selegiline (L-deprenyl) designed to retain the catecholaminergic enhancer activity of the parent compound while eliminating its monoamine oxidase (MAO) inhibitory property. The compound occupies a mechanistically distinct position in the catecholaminergic pharmacology space: at low-to-moderate concentrations, PPAP potentiates the impulse-propagation-mediated (action-potential-dependent) release of dopamine and norepinephrine from catecholaminergic nerve terminals without producing the uncontrolled, impulse-independent monoamine efflux characteristic of amphetamine and methamphetamine. This “enhancer” mechanism, first formally described by Knoll in 1992 and subsequently elaborated in a series of publications through 2005, operates independently of MAO inhibition, presynaptic autoreceptor blockade, and classical reuptake inhibition, and instead potentiates the vesicular exocytotic release event coupled to the arriving action potential. Recent pharmacological characterization reported in 2025 has expanded the mechanistic profile by demonstrating that PPAP also acts as a potent dopamine transporter (DAT) reuptake inhibitor with an IC50 of 57.5 nM, a norepinephrine transporter (NET) inhibitor at 571 nM, and a weak serotonin transporter (SERT) inhibitor at 19,000 nM, placing it in a dual-mechanism category that combines enhancer activity with catecholamine reuptake inhibition. Additional evidence suggests that PPAP and related synthetic enhancer compounds may exert their catecholaminergic effects through agonism at trace amine-associated receptor 1 (TAAR1), an intracellular G-protein-coupled receptor that modulates vesicular dopamine release through protein kinase C (PKC)-mediated phosphorylation of exocytotic machinery.

In preclinical behavioral pharmacology, PPAP facilitates learning and retention in shuttle-box avoidance paradigms, potently antagonizes tetrabenazine-induced behavioral depression, reduces immobility in the forced swimming test, and increases locomotor activity across a broad dose range (2 to 50 mg/kg in rodents) without the narrow therapeutic window and stereotypy induction that characterize amphetamine-class stimulants. The therapeutic index in animal models exceeds that of amphetamine. Structure-activity relationship studies identified the (R)-enantiomer as the pharmacologically active form, while the racemic mixture (designated MK-306) retains partial activity. PPAP served as the reference catecholaminergic activity enhancer compound in the Knoll laboratory and led directly to the development of the more potent and serotonergically active successor compound BPAP [(-)1-(benzofuran-2-yl)-2-propylaminopentane] in 1999. PPAP has been proposed as a candidate for clinical development in depression, attention deficit hyperactivity disorder (ADHD), and Alzheimer’s disease, though no human clinical trials have been completed or published. The compound is not approved by any regulatory authority for therapeutic use and is available exclusively as a research-grade preparation. This monograph reviews the chemistry, synthesis, and stereochemistry of PPAP-HCl; the dual enhancer and reuptake-inhibitor pharmacology; the preclinical behavioral and neurochemical evidence base; the comparative assessment of five catecholaminergic and monoaminergic enhancer or stimulant candidates against PPAP on five competency standards; and the sourcing, reconstitution, and handling considerations for laboratory work.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1528Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
Cariprazine

Plain-language summaryIntrigue 69 / 100

Cariprazine (Vraylar) is a Hungarian-developed dopamine D2/D3 partial agonist from Gedeon Richter and AbbVie, approved by the FDA in 2015. It is structurally and mechanistically related to aripiprazole, but with a meaningful refinement: it preferentially binds the D3 receptor over D2 by roughly 6-fold. D3 receptors are concentrated in brain regions involved in motivation and cognition, which gives cariprazine a unique profile useful for the negative symptoms of schizophrenia (apathy, social withdrawal, cognitive blunting) where most antipsychotics fail. It is approved for schizophrenia, bipolar mania, bipolar depression, and as add-on for major depression. The very long half-lives of its active metabolites mean it takes weeks to reach steady state and weeks to wash out. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

62/100

A D3-dominant partial agonist with real clinical differentiation but a closing research novelty window

Cariprazine is one of those compounds where the mechanistic story is legitimately interesting but the research window has mostly closed. FDA-approved since 2015 across four indications, its clinical career is mature. The registration trials are done, the safety profile is established, and the field has moved from asking “does it work” to “how does it perform in practice against the other partial agonists.” That shift matters for how you score research relevance.

The D3 story is what keeps it on the radar. A Ki of roughly 0.085 nM at D3 is not a rounding error. That affinity actually exceeds endogenous dopamine’s own affinity for the same receptor, and no other marketed antipsychotic comes close to the D3 occupancy cariprazine produces at clinical doses. The biological rationale is solid: D3 receptors are enriched in mesolimbic and prefrontal circuits governing motivation, reward anticipation, and cognitive drive, which are exactly the domains where D2-heavy antipsychotics consistently fail. The 5-HT1A partial agonism (Ki ~2.6 nM) layers on top, adding complexity to any clean mechanistic interpretation but also contributing to its profile on anhedonia and depressive features.

The PRIDE trial is the clearest translational demonstration of that theory. Cariprazine versus risperidone in a predominantly negative-symptom schizophrenia population: statistically and clinically significant differences on the PANSS negative subscale and PSP. Risperidone is a competent D2 antagonist and cariprazine beat it on the domain D2 drugs have never served well. Thats real.

What we like: the D3 differentiation story holds up under scrutiny, the evidence base is among the strongest in the library (multiple phase 3 RCTs with hard primary endpoints), and the active metabolite pharmacology (DCAR and DDCAR together produce an effective half-life approaching one week) offers a pharmacokinetically unusual model that has its own research utility in steady-state receptor occupancy studies.

What we dont like: by 2026 this isnt a discovery compound. The primary clinical questions are answered. If you’re running a bench program, cariprazine is most likely to appear as a comparator or as a probe for D3 receptor contribution experiments, not as the main subject. The 5-HT1A activity complicates clean D3 interpretations, and investigators who need a tighter D3 probe may prefer less clinically cluttered ligands. The novelty clock started in 2002 and its audible.

Honest take: serious compound, legitimate clinical differentiation, fading research frontier. Investigators working on D3 circuitry, negative symptom pharmacology, or partial agonism dose-response modeling will find real utility here. For most other research programs, its a reference point rather than a primary target.

Novelty

38

Mechanism promise

65

In-category differentiation

65

Evidence quality

78

Translational signal

72

Research bench value

58

Rationale Cariprazine holds genuine mechanistic distinction within the dopamine partial agonist class via subnanomolar D3 affinity exceeding endogenous dopamine, with strong multi-trial clinical evidence across four approved indications; novelty is suppressed because the compound is a 2015-approved drug whose primary clinical questions are settled, and bench utility is real but narrowly concentrated in D3 receptor biology and negative-symptom circuitry research.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Dopamine D3-preferring D3/D2 receptor partial agonist and serotonin 5-HT1A receptor partial agonist atypical antipsychotic

A D3-preferring dopamine receptor partial agonist developed by Gedeon Richter as an atypical antipsychotic, distinguished from aripiprazole and brexpiprazole by subnanomolar D3 affinity exceeding that of endogenous dopamine and by the generation of two pharmacologically active long-lived metabolites that collectively produce an effective half-life of approximately one week.

Abstract

Cariprazine (RGH-188; marketed as Vraylar) is a dopamine D3-preferring D3/D2 receptor partial agonist and serotonin 5-HT1A receptor partial agonist approved by the United States Food and Drug Administration for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder, depressive episodes associated with bipolar I disorder (bipolar depression), and adjunctive treatment of major depressive disorder in adults with inadequate response to antidepressant therapy. The compound was discovered by Gedeon Richter Plc. in Budapest, Hungary, first synthesized in 2002, and advanced through clinical development in partnership with Forest Laboratories (subsequently Actavis, Allergan, and AbbVie), receiving initial FDA approval in September 2015 and European Medicines Agency approval in 2017 under the trade name Reagila. Cariprazine is pharmacologically distinguished from the other clinically marketed dopamine partial agonist antipsychotics (aripiprazole, brexpiprazole) by its exceptionally high affinity for the dopamine D3 receptor (Ki approximately 0.085 nM), which exceeds the affinity of endogenous dopamine for the same receptor and produces a degree of D3 occupancy at clinical doses that is not achievable by any other marketed antipsychotic. The D3-preferring profile, with approximately 6- to 8-fold selectivity over D2, is hypothesized to underwrite the compound’s differentiated efficacy on negative symptoms of schizophrenia, cognitive impairment, anhedonia, and motivational deficits, domains that are poorly served by D2-predominant antipsychotic pharmacology. Cariprazine additionally binds the serotonin 5-HT1A receptor as a partial agonist (Ki approximately 2.6 nM) and the serotonin 5-HT2B receptor with high affinity (Ki approximately 0.6 nM), while showing low affinity for histamine H1, muscarinic, and alpha-1 adrenergic receptors, a selectivity profile that predicts low sedation, low anticholinergic burden, and low orthostatic hypotension relative to the broader atypical antipsychotic class.

The pharmacokinetic profile of cariprazine is dominated by its two major active metabolites, desmethyl-cariprazine (DCAR) and didesmethyl-cariprazine (DDCAR), both of which possess pharmacological activity comparable to the parent compound at D3, D2, and 5-HT1A receptors. The parent compound has a half-life of 2 to 4 days; DCAR has a half-life of 1 to 2 days; and DDCAR, the predominant circulating active species at steady state, has a half-life of 1 to 3 weeks. The effective half-life of total active moieties is approximately 1 week, with steady-state equilibrium achieved at approximately 3 weeks of daily dosing. This pharmacokinetic profile has important implications for dose titration (clinical effects may lag dose changes by days to weeks), for drug-drug interactions (strong CYP3A4 inhibitors require dose reduction; strong CYP3A4 inducers are contraindicated), and for washout after discontinuation (pharmacological activity persists for several weeks).

The clinical evidence base comprises multiple Phase 2 and Phase 3 randomized controlled trials across four approved indications, a head-to-head Phase 3b trial against risperidone for predominant negative symptoms of schizophrenia (demonstrating statistically significant superiority on the PANSS factor score for negative symptoms), and relapse prevention data in schizophrenia. The adverse-event profile is characterized by akathisia and extrapyramidal symptoms as the most common treatment-emergent adverse events (dose-dependent, typically mild to moderate), with a comparatively favorable metabolic profile (minimal weight gain, negligible effects on glucose and lipid parameters) and low prolactin elevation relative to other atypical antipsychotics. This monograph reviews the chemistry, receptor pharmacology, pharmacokinetics, preclinical pharmacology, clinical evidence across all approved and investigational indications, sourcing and quality verification, reconstitution and handling, stack interactions, adverse-event signal, and a comparative assessment of five alternative atypical antipsychotic agents against cariprazine on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1503Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
Arimistane

Our opinion on this compoundEstablished workhorse

34/100

Supplement-market steroidal AI with an interesting dual mechanism that pharmaceuticals already outclass

Look, the aromatase inhibitor class isn’t lacking for research compounds. Exemestane, letrozole, anastrozole — these are approved drugs with deep phase 2/3 trial histories, crystal structures of their target complexes, and decades of mechanistic clarity. Arimistane entering that conversation as a dietary supplement ingredient doesn’t earn it a seat at the table just because it shares a steroidal backbone and a suicide-inhibitor mechanism with exemestane.

The endogenous biosynthetic origin story is real and its the most honest differentiator Arimistane has. It is a downstream metabolite of 7-keto-DHEA, produced through CYP7B1 and 11-beta-HSD oxidation and dehydration — so calling it “natural” in a biochemical sense is technically correct. But endogenous origin doesnt confer research priority. The question is whether the compound tells you something you couldn’t learn from exemestane, and mostly it doesn’t.

The interesting exception is the 11-beta-HSD type 1 angle. If Arimistane genuinely competitively inhibits 11-beta-HSD1 while simultaneously inactivating CYP19A1 irreversibly, thats a composite pharmacology that no pharmaceutical AI currently on the market replicates in one molecule. The androgen/cortisol crosstalk hypothesis — where reducing local cortisol regeneration and reducing estrogen simultaneously produces a distinct hormonal shift — is mechanistically coherent and underexplored. We’d want to see clean in vitro Ki values and a serious in vivo read on 11-beta-HSD1 occupancy at physiologically relevant concentrations before calling this a real dual probe, and right now that data is thin.

The evidence base is mostly in vitro aromatase inhibition assays, rodent pharmacology, and limited human hormonal tolerability data accumulated in the supplement context. Regulatory actions from FDA flagging Arimistane as an illegal new drug ingredient in finished products further complicate sourcing and signal that institutional research using this compound carries compliance overhead it frankly doesn’t justify when exemestane is commercially available as a pharmaceutical reference standard.

Honestly, the researchers who’d find Arimistane most useful are those specifically studying the 11-beta-HSD1/aromatase dual-inhibition question in adipose or hypothalamic tissue models. That’s a real question worth asking. But thats a narrow niche, and the compound needs better mechanistic characterization before it earns serious bench time. For general aromatase biology, reach for exemestane. For 11-beta-HSD1 biology, use a selective inhibitor. Arimistane’s dual activity is more of a confound than a feature until the pharmacology is properly decomposed.

Novelty

28

Mechanism promise

45

In-category differentiation

28

Evidence quality

32

Translational signal

38

Research bench value

35

Rationale Arimistane sits in well-trodden steroidal aromatase inhibitor territory where exemestane — an FDA-approved analogue — already defines the class with rigorous phase 3 data behind it. The 11-beta-HSD1 inhibitory co-activity is the only genuinely differentiating angle, but it remains poorly characterized and hasn’t driven serious clinical development; the compound’s decade in the bodybuilding supplement channel has done more to muddy its research credibility than to build it.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Steroidal mechanism-based (suicide) aromatase inhibitor derived from the 7-oxo-dehydroepiandrosterone metabolic pathway

A naturally occurring androstadienedione metabolite of 7-keto-DHEA that functions as an irreversible steroidal aromatase inactivator, distinguished from pharmaceutical aromatase inhibitors by its endogenous biosynthetic origin and concurrent reported activity on cortisol regulation through competitive inhibition of 11-beta-hydroxysteroid dehydrogenase type 1.

Abstract

Androsta-3,5-diene-7,17-dione, marketed and commonly known as Arimistane, is a steroidal mechanism-based irreversible inhibitor of aromatase (cytochrome P450 19A1, CYP19A1) that occupies a distinctive position in the landscape of estrogen-modulating compounds. Structurally, it is an androstadienedione bearing conjugated 3,5-diene unsaturation in the A/B ring system and a 7-oxo group on the B ring, with the characteristic 17-ketone of the androstane series. The compound is a downstream metabolite of 7-keto-dehydroepiandrosterone (7-keto-DHEA, 3-beta-hydroxyandrost-5-ene-7,17-dione), itself produced from dehydroepiandrosterone (DHEA) by hepatic cytochrome P450 7B1 (CYP7B1) or CYP3A-mediated 7-alpha-hydroxylation followed by 11-beta-hydroxysteroid dehydrogenase (11-beta-HSD) oxidation at the 7-position and subsequent dehydration. This endogenous biosynthetic origin distinguishes Arimistane from fully synthetic aromatase inhibitors such as exemestane, letrozole, and anastrozole.

The aromatase-inhibitory mechanism of Arimistane belongs to the type I (steroidal, mechanism-based) class characterized by Covey and colleagues in the early 1980s for the structurally related androst-5-ene-7,17-dione series [1, 2]. Mechanism-based inhibition proceeds through initial competitive binding of the steroidal inhibitor to the substrate-binding pocket of aromatase, followed by enzyme-catalyzed oxidative processing that generates a reactive intermediate capable of forming a covalent bond with amino acid residues at or near the active site. The covalent modification permanently inactivates the enzyme molecule; restoration of aromatase activity requires de novo protein synthesis rather than simple inhibitor dissociation. This irreversible (“suicide”) mechanism produces sustained estrogen suppression that persists beyond the plasma residence time of the parent compound, a pharmacodynamic feature shared with the clinically approved steroidal aromatase inactivator exemestane.

Beyond aromatase inhibition, Arimistane has been reported to modulate cortisol metabolism through competitive inhibition of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-HSD1), the microsomal enzyme that catalyzes the reduction of cortisone to the biologically active glucocorticoid cortisol in liver, adipose tissue, and central nervous system. This activity, attributed to the 7-oxo-androstane structural motif shared with 7-keto-DHEA and its metabolites, is proposed to reduce local cortisol regeneration without affecting adrenal cortisol synthesis directly. The dual aromatase-inhibitory and cortisol-modulatory profile has driven interest in Arimistane within the bodybuilding and sports-performance supplement industry, where the compound has been marketed as a post-cycle therapy agent and estrogen-control supplement.

The regulatory status of Arimistane is restrictive. The United States Food and Drug Administration (FDA) has determined that androsta-3,5-diene-7,17-dione does not meet the statutory definition of a dietary ingredient under section 201(ff)(1) of the Federal Food, Drug, and Cosmetic Act, and has issued multiple warning letters to supplement manufacturers marketing products containing the compound [3]. The World Anti-Doping Agency (WADA) added Arimistane to the Prohibited List in 2017 under the category of hormone and metabolic modulators (class S4), specifically as an aromatase inhibitor [4]. The compound is not approved as a pharmaceutical in any jurisdiction.

The clinical evidence base for Arimistane is sparse relative to pharmaceutical aromatase inhibitors. No registration-quality clinical trials have been conducted. Published human data are limited to manufacturer-sponsored tolerability assessments and analytical chemistry studies characterizing the compound as a urinary metabolite of 7-keto-DHEA in anti-doping contexts [5]. The pharmacological characterization rests principally on in vitro aromatase inhibition assays, structure-activity relationship inference from the broader androstene-7,17-dione series studied by Covey, Brodie, and colleagues in the 1980s and 1990s [1, 2, 6], and extrapolation from the more extensive clinical pharmacology of the structurally related steroidal aromatase inactivator exemestane. This monograph reviews the chemistry, biosynthetic origin, mechanism of aromatase inactivation, reported pharmacokinetics, preclinical and clinical evidence, sourcing and quality considerations, stack interactions, adverse-event signal, and a comparative assessment of Arimistane against five alternative aromatase-modulating compounds on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1539Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
KW-6356

Our opinion on this compoundNovel, promising

63/100

Second-gen A2A inverse agonist with solved crystal structure, sub-nanomolar affinity, and real Phase 2 PD data

Look, the A2A antagonist story in Parkinson’s research has a complicated history. Istradefylline made it to approval (NOURIANZ), but the class got its share of high-profile failures — preladenant and tozadenant both ran into clinical walls that had nothing to do with the basic A2A hypothesis. KW-6356 earns attention not because it’s a better version of the same thing, but because it introduces two pharmacologically distinct properties that the first generation simply did not have: insurmountable antagonism and inverse agonism.

That second property is the interesting one. Most receptor antagonists compete with endogenous agonists and can be overcome if you flood the system with enough adenosine. Inverse agonists go further — they actively suppress constitutive receptor activity, the signaling that happens even in the absence of agonist. At A2A receptors in the basal ganglia, where constitutive activity is non-trivial, that’s a real distinction. The Kyowa Kirin structural work deposited at PDB 8GNE pins down exactly which residues (His250/6.52 and Trp246/6.48) drive the inverse agonist effect, giving researchers something unusually solid to work with when designing follow-on chemistry.

The affinity numbers are genuinely striking. A Ki of 0.12 nM and greater than 100-fold selectivity over A1, A2B, and A3 subtypes puts this well above what the first-gen antagonists could manage. Istradefylline sits around pKi 7.9; KW-6356 at 9.93 isn’t just incrementally better — that’s a different order of magnitude for receptor engagement.

The clinical record is real but not yet decisive. Phase 2a data in 168 early PD patients, followed by Phase 2b adjunct-to-levodopa work, gives the compound a human evidence base that most small-molecule research targets lack. What we dont yet have is Phase 3 confirmation or regulatory action. The translational signal is solid but incomplete. Thats worth flagging before treating the Phase 2 data as settled.

For bench investigators, the probe value here extends well beyond PD. A2A receptors are active in neuroinflammation research and in cancer immunology, where A2A-mediated immunosuppression in the tumor microenvironment is a live question with its own clinical programs (notably in combination with checkpoint inhibitors). A compound with a solved crystal structure, documented inverse agonist activity, and sub-nanomolar affinity is a genuinely useful tool across those programs. We think that cross-indication bench utility is underappreciated relative to the PD-focused clinical narrative.

The honest limitation: KW-6356 is still operating in a class with a rocky track record and against a disease where everything is harder than it looks. Its mechanistic properties are real and well-characterized, but the class has promised more than it’s delivered at the regulatory finish line. We score it as a well-mechanized, clinically-supported research compound in a legitimately interesting receptor biology space — not a sure thing, but a serious target for investigators working the A2A axis.

Novelty

58

Mechanism promise

68

In-category differentiation

67

Evidence quality

60

Translational signal

60

Research bench value

65

Rationale KW-6356 scores on the strength of genuine pharmacological differentiation from the first-gen A2A class (inverse agonism, insurmountable antagonism, 100-fold affinity gain) combined with structural mechanistic clarity and Phase 2 clinical confirmation. Evidence quality and translational signal are solid but not Phase-3-complete, which holds the overall below the high-70s despite the mechanistic strength.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective non-xanthine adenosine A2A receptor antagonist and inverse agonist

A second-generation, non-xanthine adenosine A2A receptor antagonist and inverse agonist developed by Kyowa Kirin as a successor to istradefylline for the treatment of Parkinson’s disease, distinguished by insurmountable antagonism, inverse agonist activity, and approximately 100-fold greater receptor affinity than the first-generation A2A antagonist class.

Abstract

KW-6356 (sipagladenant; CAS 858979-50-7) is a selective, non-xanthine adenosine A2A receptor antagonist and inverse agonist developed by Kyowa Kirin Co., Ltd. (formerly Kyowa Hakko Kirin) as a next-generation successor to istradefylline (NOURIANZ/NOURIAST) for the treatment of motor and non-motor symptoms of Parkinson’s disease. The compound exhibits approximately 100-fold greater binding affinity for the human adenosine A2A receptor than istradefylline (pKi 9.93 versus approximately 7.9), with a Kd of 0.13 nM and a Ki of 0.12 nM at the human A2A receptor, and demonstrates greater than 100-fold selectivity over the A1, A2B, and A3 adenosine receptor subtypes [1]. In contrast to istradefylline, which acts as a surmountable antagonist, KW-6356 exhibits two pharmacologically distinct properties: insurmountable antagonism (the capacity to suppress receptor signaling in a manner that cannot be fully overcome by increasing agonist concentration) and inverse agonism (the capacity to reduce constitutive, agonist-independent receptor activity below basal levels). X-ray crystallography of the KW-6356-bound human A2A receptor at 2.30 angstrom resolution (PDB: 8GNE) has revealed that interactions with His250 (position 6.52) and Trp246 (position 6.48) are essential for the inverse agonist activity, while deep orthosteric pocket contacts and stabilization of the extracellular loop conformation contribute to the insurmountable antagonism [1].

The clinical development program evaluated KW-6356 in two pivotal Phase 2 studies in Japanese Parkinson’s disease populations. A Phase 2a randomized, double-blind, placebo-controlled monotherapy trial in 168 patients with early, untreated Parkinson’s disease demonstrated that once-daily oral KW-6356 at 3 mg and 6 mg produced improvements in MDS-UPDRS Part III motor scores (least-squares mean changes from baseline to week 12 of -5.37 and -4.76, respectively, versus -3.14 for placebo) [2]. A subsequent Phase 2b randomized, double-blind, placebo-controlled adjunct-to-levodopa trial in 503 patients with levodopa-treated Parkinson’s disease demonstrated statistically significant improvements in MDS-UPDRS Part III motor scores at both 3 mg (p = 0.006 versus placebo) and 6 mg (p = 0.049 versus placebo), with additional reductions in mean daily OFF time in the key secondary endpoint and improvements on the PD Sleep Scale-2 in post-hoc analysis [3, 4]. Preclinical pharmacology in MPTP-treated common marmosets confirmed dose-dependent reversal of motor disability at oral doses up to 1 mg/kg, with anti-parkinsonian activity significantly greater than that of istradefylline and a low risk of inducing dyskinesia [5, 6].

Pharmacokinetics in healthy volunteers demonstrated linear exposure after single oral doses of 1 to 60 mg, with a mean terminal elimination half-life of 18.4 to 43.1 hours (mean approximately 22.9 hours), a time to peak plasma concentration of 0.75 to 3 hours, and an active metabolite (M6) with comparable A2A antagonist and inverse agonist potency and an elimination half-life of approximately 4.34 hours [7, 8]. Population pharmacokinetic modeling identified food status, baseline serum albumin, and baseline body weight as covariates, but none had clinically meaningful impact on KW-6356 or M6 exposure [8]. The compound was well tolerated in Phase 1 studies at single doses up to 60 mg and multiple doses up to 24 mg once daily for 14 days, with no clinically meaningful changes in vital signs, body weight, laboratory parameters, or electrocardiograms [7]. The most common adverse events in the Phase 2a monotherapy trial were constipation (7.3 percent at 3 mg, 6.9 percent at 6 mg) and nasopharyngitis (7.3 percent at 3 mg, 8.6 percent at 6 mg) [2].

Despite positive proof-of-concept results across both monotherapy and adjunct-to-levodopa settings, Kyowa Kirin announced discontinuation of the KW-6356 development program in July 2022, citing evaluation of the global regulatory landscape, development hurdles, and timelines for potential market entry rather than efficacy or safety concerns [9]. The discontinuation followed Lundbeck’s earlier decision to return ex-Asia development rights to Kyowa Kirin. No Phase 3 trials were initiated. This monograph documents the chemistry, structural pharmacology, receptor binding and selectivity profile, preclinical and clinical evidence base, pharmacokinetics, safety signal, and a comparative assessment of KW-6356 against five adenosine A2A receptor antagonists on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1527Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
Sildenafil

Our opinion on this compoundEstablished, active research

46/100

Mature PDE5 inhibitor with outstanding clinical evidence and real but unsettled emerging signals in neurodegeneration and cardioprotection

Look, sildenafil is pharmacologically important in a historical sense, but as an active research target right now it sits solidly in the middle of the pack and thats the honest read. The mechanism has been characterized across nearly three decades of academic and industrial work: selective PDE5 inhibition, downstream cGMP elevation in vascular smooth muscle and the corpus cavernosum, reduced pulmonary vascular resistance via the same pathway. Two FDA approvals, multiple phase 3 registrations, a massive post-marketing surveillance dataset spanning tens of millions of patient-years. For its approved indications, the evidence base is about as clean as it gets in pharmacology.

The interesting open question isn’t whether PDE5 inhibition works in the vasculature. That’s settled. The question is whether cGMP-mediated effects in non-vascular tissues are pharmacologically meaningful in new contexts. Here’s where sildenafil becomes worth watching again. A 2021 Nature Aging analysis from the Fang group at Cleveland Clinic used insurance claims data and Alzheimer’s disease protein interaction networks to flag sildenafil as one of the stronger computational hits for reduced AD incidence, reporting roughly a 69% hazard reduction in a propensity-matched cohort of over seven million patients. It’s observational data, not a controlled trial, and the mechanistic hypothesis involves cGMP-dependent tau phosphorylation reduction plus improved cerebral perfusion. Causality is genuinely unresolved. An ADDF-supported Phase 2 trial was ongoing as of 2024 and hasn’t reported primary endpoints.

What we like about sildenafil as a bench tool is the combination of a clean, validated mechanism with tissue expression data that the original cardiac development program underexplored. PDE5 is expressed in hippocampal neurons, cerebellar Purkinje cells, and cardiac myocytes in ways that create real utility for groups studying cyclic nucleotide signaling in neurodegeneration or ischemia-reperfusion injury. The cardiac preconditioning literature, ischemic protection via cGMP amplification in rodent models, has multi-lab replication and a plausible mechanistic arrow.

What we dont love: there are now four approved PDE5 inhibitors plus riociguat, and for most bench questions the differentiation is modest. Tadalafil’s longer half-life and subtly different selectivity profile make it a real competitor for chronic dosing studies. Avanafil offers improved PDE6 selectivity if retinal cross-inhibition is a confounder. Sildenafil’s main distinguishing claim right now is that Alzheimer’s association signal, which is specific to this compound in the dataset and not obviously class-driven. That’s genuinely interesting but not yet actionable at the level of a funded mechanistic program.

A score of 46 reflects that position accurately. Outstanding clinical compound, proven bench probe for cGMP biology in multiple tissues, but not a frontier target. The novel questions are real; they’re just not resolved enough to elevate it further.

Novelty

20

Mechanism promise

40

In-category differentiation

35

Evidence quality

78

Translational signal

70

Research bench value

52

Rationale Sildenafil scores low on novelty and differentiation because it is a 27-year-old generic with three direct competitors, but it earns genuine marks on evidence quality and translational signal for its approved indications, and the Fang et al. 2021 Alzheimer’s association analysis adds a legitimate but unresolved research angle that keeps it out of the pure workhorse tier.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective phosphodiesterase type 5 (PDE5) inhibitor of the pyrazolopyrimidinone structural class

A pyrazolopyrimidinone-based cyclic GMP-specific phosphodiesterase type 5 inhibitor originally developed at Pfizer as an antianginal agent, repositioned as the first oral pharmacotherapy for erectile dysfunction and subsequently approved for pulmonary arterial hypertension, with an expanding preclinical evidence base in cardioprotection, neuroprotection, and vascular inflammation.

Abstract

Sildenafil (UK-92480) is a potent, competitive, and selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), the enzyme principally responsible for hydrolytic degradation of cGMP in vascular smooth muscle, the corpus cavernosum, and the pulmonary vasculature. The compound was synthesized at the Pfizer Global Research and Development laboratories in Sandwich, Kent, United Kingdom in 1989 as part of a medicinal chemistry program targeting selective PDE5 inhibition for the treatment of angina pectoris and hypertension. Phase I clinical trials revealed limited antianginal efficacy but a pronounced and reproducible effect on penile erection, prompting repositioning toward erectile dysfunction. Sildenafil received United States Food and Drug Administration (FDA) approval on 27 March 1998 as the first oral pharmacotherapy for erectile dysfunction (marketed as Viagra) and subsequently received FDA approval in June 2005 for the treatment of World Health Organization Group I pulmonary arterial hypertension (marketed as Revatio).

The pharmacological mechanism is inhibition of PDE5 at the catalytic site with an IC50 of approximately 3.5 nanomolar and selectivity over PDE1 through PDE4 of 80- to 19,000-fold, with approximately 10-fold selectivity over the structurally related retinal PDE6, the latter accounting for the dose-dependent visual disturbances observed clinically [1, 2]. PDE5 inhibition potentiates the nitric oxide (NO)/soluble guanylyl cyclase (sGC)/cGMP signaling cascade: in tissues where NO release occurs (penile corpus cavernosum during sexual stimulation, pulmonary vascular endothelium), sildenafil amplifies the downstream smooth muscle relaxation by preventing cGMP breakdown. The compound does not directly initiate smooth muscle relaxation in the absence of NO signaling, a pharmacological distinction that differentiates PDE5 inhibitors from direct NO donors and from soluble guanylyl cyclase stimulators.

Pharmacokinetics are characterized by rapid oral absorption (time to peak plasma concentration approximately 60 minutes under fasting conditions), moderate absolute oral bioavailability of approximately 41 percent (limited by hepatic first-pass metabolism), a plasma elimination half-life of approximately 3 to 5 hours, and high plasma protein binding of approximately 96 percent [3, 4]. Metabolism is predominantly hepatic via cytochrome P450 3A4 (CYP3A4, major pathway) and CYP2C9 (minor pathway), producing the active N-desmethyl metabolite (UK-103,320) that retains approximately 50 percent of the parent compound potency at PDE5 and has a similar terminal half-life [3]. The CYP3A4 dependence creates clinically significant drug-drug interactions with strong CYP3A4 inhibitors (ritonavir, ketoconazole, itraconazole, erythromycin), which can elevate sildenafil plasma concentrations by 3- to 11-fold.

The clinical evidence base spans two FDA-approved indications (erectile dysfunction and pulmonary arterial hypertension) and multiple investigational applications including Raynaud phenomenon, heart failure, altitude sickness, and neuroprotection. The SUPER-1 trial in 278 patients with pulmonary arterial hypertension demonstrated significant improvement in six-minute walk distance across all sildenafil dose groups (20, 40, and 80 mg three times daily) compared to placebo [5]. A 2024 dose-ranging trial by Hoeper et al. further demonstrated dose-dependent benefit, with the 80 mg three times daily group achieving a median gain of 52 meters in six-minute walk distance [6]. Preclinical pharmacology has established cardioprotective effects against ischemia-reperfusion injury through mitochondrial ATP-sensitive potassium channel opening, neuroprotective effects in rodent stroke and neurodegeneration models through cGMP-mediated anti-apoptotic signaling, and anti-inflammatory effects through suppression of NF-kappaB-driven cytokine release.

The compound is well tolerated at approved doses. Principal adverse events are headache (16 percent), flushing (10 percent), dyspepsia (7 percent), nasal congestion (4 percent), and dose-dependent visual disturbances (chromatopsia, increased light sensitivity) reflecting PDE6 cross-inhibition in retinal photoreceptors [7]. The critical safety concern is the absolute contraindication with organic nitrates and nitric oxide donors, where co-administration produces synergistic and potentially fatal hypotension through additive cGMP-mediated vasodilation [8]. This monograph reviews the chemistry, synthesis, and structural pharmacology of sildenafil; the molecular mechanism across PDE isoforms; comprehensive human pharmacokinetics; the clinical evidence base across approved and investigational indications; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a comparative assessment of five PDE5 inhibitor and vasodilator alternatives against sildenafil on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1556Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
Clenbuterol

Our opinion on this compoundEstablished, active research

50/100

Mature beta-2 agonist with distinctive PK and a surprising alpha-synuclein research angle

Look, clenbuterol is a 1967 compound and nobody’s pretending its core pharmacology is news. The beta-2 adrenoceptor is one of the most thoroughly characterized GPCRs in pharmacology, and the downstream cAMP/PKA signaling is textbook material at this point. So the score here reflects what it actually is: an established compound with a genuinely unusual pharmacokinetic profile and a set of research angles that keep it relevant in ways most beta-2 agonists simply aren’t.

What differentiates it mechanistically isn’t the receptor binding but the PK and tissue distribution profile. The combination of roughly 70-80% oral bioavailability with a 25-39 hour elimination half-life is essentially unique in its class. Salbutamol has a 1.6 hour half-life with poor systemic oral activity; formoterol is an order of magnitude less potent for repartitioning work. Clenbuterol’s long half-life allows stable receptor occupancy conditions that can’t be replicated with short-acting beta-2 agonists, and that matters considerably for chronic muscle biology experiments where trough concentrations drive the anabolic signal.

The skeletal muscle repartitioning story is real and well-replicated across multiple independent labs in rodent and livestock systems. The IGF-1 pathway crosstalk via cAMP-dependent signaling, the mTOR activation, anti-atrophy effects through suppression of MAFbx/atrogin-1 expression – these are established findings. Clinical signals in muscle-wasting contexts, including spinal and bulbar muscular atrophy and ALS, are modest but genuine, and the cardiac bridge-to-recovery literature adds another translational angle that most beta-2 agonists dont have.

Here’s what actually elevates this compound in our assessment: the alpha-synuclein story. Mittal and colleagues (Science, 2017) analyzed Norwegian prescription registry data and found that beta-2 agonist use correlated with significantly reduced Parkinson’s disease incidence, while beta-blocker use showed the opposite association. Follow-up mechanistic work demonstrated that clenbuterol suppresses SNCA transcription through increased H3K27 acetylation at the gene promoter. Thats genuinely unexpected pharmacology for a compound you’d otherwise file under bronchodilators, and it opened a neurodegeneration research program that didn’t exist before that paper landed.

What we dont love: beta-2 receptor desensitization is rapid and well-documented, which complicates chronic dosing protocols in any preclinical model and needs to be designed around carefully. Cardiac toxicity at supratherapeutic exposures is real – the histopathology literature on ventricular hypertrophy and myocardial necrosis is not ambiguous. The regulatory status also creates friction: not FDA-approved for human use, banned by WADA, flagged in veterinary food safety contexts. The preclinical toolkit here is genuinely strong. The clinical research pathway is complicated.

For investigators focused on muscle-wasting biology, alpha-synuclein-driven neurodegeneration, or beta-2 adrenergic pharmacology in cardiac remodeling contexts, clenbuterol remains a distinctive research tool that earns its place in a serious library. Not a frontier compound. Not a workhorse coasting on reputation either.

Novelty

35

Mechanism promise

48

In-category differentiation

55

Evidence quality

48

Translational signal

60

Research bench value

62

Rationale Primary mechanism is well-understood beta-2 agonism, but the 25-39h half-life and high oral bioavailability are genuinely unusual in the class and enable muscle biology experiments that short-acting alternatives can’t replicate; the 2017 Mittal et al. SNCA transcription finding opened a real neurodegeneration research program that keeps the compound relevant beyond its original indication.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective beta-2 adrenergic receptor agonist with anabolic, lipolytic, and bronchodilatory activity

A long-acting phenylaminoethanol beta-2 adrenoceptor agonist developed at Boehringer Ingelheim as a bronchodilator, distinguished from other sympathomimetic beta-agonists by exceptional oral bioavailability, a prolonged elimination half-life of 25 to 39 hours, and potent repartitioning activity on skeletal muscle and adipose tissue that has driven extensive preclinical and clinical investigation in muscle-wasting disorders, body composition, and neuromuscular disease.

Abstract

Clenbuterol (4-amino-alpha-[[(1,1-dimethylethyl)amino]methyl]-3,5-dichlorobenzyl alcohol; NAB 365) is a selective, long-acting beta-2 adrenergic receptor agonist originally synthesized in 1967 at the Thomae research facility of Boehringer Ingelheim in Biberach, Germany, and approved in 1976 in that country for the treatment of reversible airway obstruction in asthma and chronic obstructive pulmonary disease. The compound acts through stimulation of the beta-2 adrenoceptor, a seven-transmembrane G-protein-coupled receptor that activates adenylyl cyclase, elevates intracellular cyclic adenosine monophosphate, and engages protein kinase A signaling cascades in airway smooth muscle, skeletal muscle, adipose tissue, and hepatocytes. In airway smooth muscle the principal consequence is bronchodilation; in skeletal muscle and adipose tissue the consequences are protein accretion and lipolysis, respectively, producing a body-composition repartitioning effect that has generated an extensive preclinical and applied research literature spanning livestock science, sports pharmacology, and clinical investigation in muscle-wasting disease.

Pharmacokinetics in humans are characterized by rapid oral absorption (bioavailability approximately 70 to 80 percent), minimal hepatic first-pass metabolism, a prolonged terminal elimination half-life of 25 to 39 hours (substantially longer than the structurally related short-acting beta-2 agonists salbutamol and terbutaline), and predominant renal excretion of unchanged drug. The extended half-life supports once- or twice-daily oral dosing and produces measurable plasma accumulation on chronic administration, reaching steady state in approximately 4 days. Five minor metabolites have been identified in human and animal studies, none with significant pharmacological activity at the beta-2 receptor.

The compound is approved for human bronchospastic indications in multiple European and Latin American jurisdictions but has never received approval from the United States Food and Drug Administration for human use. In the United States, clenbuterol hydrochloride is approved solely for veterinary use as Ventipulmin Syrup (Boehringer Ingelheim Vetmedica) for the management of airway obstruction in horses, under a New Animal Drug Application approved by the FDA in 1998. The compound is classified as a prohibited substance under the World Anti-Doping Agency Prohibited List (category S1.2, other anabolic agents) and is banned in competition and out-of-competition in all sports under the WADA Code. Its use as a growth-promoting agent in food-producing animals is prohibited in the European Union, the United States, and China, though enforcement challenges have produced recurring food-safety incidents.

Beyond the registered bronchodilator indication, the principal research applications of clenbuterol are in neuromuscular disease, where pilot and open-label clinical trials have demonstrated safety and preliminary efficacy signals in spinal and bulbar muscular atrophy, amyotrophic lateral sclerosis, and spinal muscular atrophy; in skeletal muscle physiology, where the compound is the reference beta-2 agonist for studying adrenergic regulation of protein synthesis, proteolysis, and fiber-type transitions; and in cardiac biology, where the compound has been studied as a bridge-to-recovery adjunct in patients with heart failure supported by left ventricular assist devices. The cardiac research application is notable given the concurrent identification of dose-dependent myocardial toxicity in animal models and in clinical case reports of supratherapeutic use, producing a narrow therapeutic index for cardiac applications that remains an active area of investigation.

This monograph reviews the chemistry, synthesis, and stereochemistry of clenbuterol; the receptor pharmacology and downstream signaling; the comprehensive human pharmacokinetic record; preclinical pharmacology across muscle, adipose, and cardiac tissue; the clinical evidence base across bronchospastic, neuromuscular, cardiac, and body-composition indications; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications; adverse-event signal including cardiac toxicity; and a structured comparative assessment of five alternative beta-2 adrenergic agonists against clenbuterol on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1533Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
L-Carnitine

Our opinion on this compoundResearch workhorse

30/100

FDA-approved mitochondrial cofactor with fully mapped biology and minimal frontier research value

Look, L-Carnitine is not a research compound in any meaningful frontier sense. It’s a cofactor. The biology has been worked out since Fritz identified its role in fatty acid oxidation in 1955, and by the time McGarry and Foster had fully characterized CPT I, CACT, and CPT II in the 1980s, the mechanism was essentially closed. Theres nothing left to discover about what levocarnitine does at the molecular level. That’s not an insult, it’s just the reality: the compound is an obligate shuttle for long-chain fatty acyl-CoA esters across the inner mitochondrial membrane, and that job is completely understood.

What it does have is an unusually clean FDA approval story. Carnitor has been approved for primary systemic carnitine deficiency, secondary deficiency in organic acidemias, and hemodialysis-related carnitine loss. Those indications rest on real clinical data, not preclinical extrapolation. The hemodialysis population in particular shows robust and replicated signal, because ESRD patients on long-term dialysis lose carnitine faster than they can synthesize it and the replacement effect is measurable. The cardiovascular secondary prevention literature is more complicated, with a 2013 JAMA Internal Medicine meta-analysis showing modest but real reductions in mortality and ventricular arrhythmia post-MI, though the effect size doesn’t set the field on fire.

For a serious bench investigator, the honest value proposition is narrow. If you’re studying primary carnitine deficiency, organic acidemias, or the OCTN2 transport system specifically, L-Carnitine belongs in your toolkit. It’s also a necessary comparator if you’re evaluating the esterified derivatives. What we don’t think it offers is a reason to run a new research program in 2025. ALCAR has a more interesting CNS bioavailability story, propionyl-L-carnitine has a distinct vascular smooth muscle angle, and neither of those is particularly novel either.

The TMAO concern adds a layer of complexity the research community is still sorting out: Koeth et al. (2013, Nature Medicine) established that gut microbiota convert L-carnitine to trimethylamine, which is then oxidized to TMAO, and elevated TMAO correlates with cardiovascular risk in epidemiological data. Whether this represents a real mechanistic liability for supplemental L-carnitine, or is confounded by red meat intake, is genuinely unresolved and that might be the most interesting open question the compound now carries. But that question belongs to microbiome researchers, not necessarily to the carnitine itself.

We rate this compound the way you’d rate a reference standard: useful in specific contexts, essential for deficiency-state research, and completely uncompelling as a novel target. A serious investigator would source it as a comparator or tool and move on.

Novelty

10

Mechanism promise

14

In-category differentiation

20

Evidence quality

62

Translational signal

58

Research bench value

33

Rationale L-Carnitine scores low on novelty and mechanism because it is a decades-old obligate cofactor with textbook-level understood biology; the CPT shuttle has been characterized since the 1970s Fritz and McGarry era. Evidence and translational scores pull the overall up modestly because the compound is an FDA-approved pharmaceutical with real clinical impact in deficiency states, but that approval actually underscores how mature and un-frontier this chemistry is.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous quaternary ammonium compound functioning as an obligate cofactor in mitochondrial long-chain fatty acid beta-oxidation via the carnitine palmitoyltransferase shuttle system

A conditionally essential nutrient and FDA-approved pharmaceutical (levocarnitine) that mediates the translocation of long-chain fatty acyl groups across the inner mitochondrial membrane, with clinical applications spanning primary and secondary carnitine deficiency, cardiovascular secondary prevention, hemodialysis support, exercise performance, male reproductive health, and neuroprotection.

Abstract

L-Carnitine (levocarnitine) is a naturally occurring, water-soluble quaternary ammonium compound biosynthesized from the amino acids lysine and methionine in liver, kidney, and brain, and obtained exogenously from dietary sources (principally red meat and dairy products) and from pharmaceutical or nutraceutical supplementation. The compound is an obligate cofactor for the carnitine palmitoyltransferase (CPT) shuttle system, the sole mechanism by which long-chain fatty acyl-coenzyme A esters cross the inner mitochondrial membrane to undergo beta-oxidation. In the absence of adequate carnitine, mitochondrial long-chain fatty acid oxidation is impaired, producing the metabolic phenotype of primary systemic carnitine deficiency: hypoketotic hypoglycemia, cardiomyopathy, skeletal myopathy, and hepatic encephalopathy. The compound was first isolated from vertebrate muscle extract by Gulewitsch and Krimberg in 1905, structurally characterized as beta-hydroxy-gamma-trimethylaminobutyric acid by Tomita and Sendju in 1927, identified as the insect growth factor vitamin BT by Fraenkel and colleagues in the 1950s, and functionally linked to fatty acid oxidation by Fritz in 1955. Its obligate role in mitochondrial bioenergetics was established through the subsequent characterization of the CPT I, carnitine-acylcarnitine translocase (CACT), and CPT II enzyme system by McGarry, Foster, Ramsay, and colleagues in the 1970s and 1980s.

L-Carnitine is approved by the United States Food and Drug Administration as levocarnitine (Carnitor, Leadiant Biosciences) for the treatment of primary systemic carnitine deficiency and for the prevention and treatment of carnitine deficiency in patients with end-stage renal disease undergoing maintenance hemodialysis. Pharmacokinetics are characterized by carrier-mediated intestinal absorption via the organic cation/carnitine transporter OCTN2 (SLC22A5), with oral bioavailability of 54 to 87 percent from dietary sources but only 14 to 18 percent from high-dose oral supplements owing to saturation of active transport. Renal handling is dominated by efficient tubular reabsorption (90 to 99 percent of filtered load) via OCTN2 at physiological plasma concentrations, with saturable reabsorption kinetics producing rapid urinary clearance of supraphysiological doses. Plasma elimination half-life is approximately 2 to 6 hours for exogenous doses; the endogenous total body pool (approximately 20 to 25 grams in a 70-kilogram adult) turns over slowly with an estimated whole-body half-life of 40 to 100 hours.

Clinical evidence for supplemental L-carnitine spans multiple therapeutic domains. In cardiovascular secondary prevention, a 2013 meta-analysis of 13 controlled trials (N = 3,629) by DiNicolantonio et al. in Mayo Clinic Proceedings reported a 27 percent reduction in all-cause mortality (OR 0.73, 95% CI 0.54 to 0.99), a 65 percent reduction in ventricular arrhythmias, and a 40 percent reduction in angina development in patients following acute myocardial infarction. In chronic heart failure, a 2017 meta-analysis of 17 trials (N = 1,625) reported significant improvements in left ventricular ejection fraction (+4.14%), stroke volume (+8.21 mL), and cardiac output (+0.88 L/min). In hemodialysis populations, Cochrane and systematic reviews have reported potential benefits for anemia, C-reactive protein reduction, and intradialytic hypotension, though evidence quality remains low to moderate. In exercise physiology, systematic reviews report benefits of 1 to 4 grams daily on VO2max, peak power output, and lactate reduction, with effect sizes dependent on dosing duration and exercise modality. In male reproductive health, meta-analyses report significant improvements in sperm motility and morphology with 1 to 3 grams daily for 3 to 6 months, though pregnancy rate improvements have not been consistently demonstrated. Acetyl-L-carnitine, a physiological ester derivative, has demonstrated efficacy in randomized controlled trials for diabetic peripheral neuropathy, with significant pain reduction and nerve fiber regeneration.

A safety consideration of growing importance is the gut microbial conversion of L-carnitine to trimethylamine (TMA), which undergoes hepatic oxidation by flavin-containing monooxygenase 3 (FMO3) to trimethylamine N-oxide (TMAO), a metabolite epidemiologically associated with increased atherosclerotic cardiovascular disease risk. The TMAO pathway is diet-dependent and microbiome-dependent, with omnivorous individuals producing substantially more TMAO from carnitine challenge than vegetarians or vegans. This monograph reviews the chemistry, biosynthesis, and transport of L-carnitine; the carnitine shuttle mechanism in molecular detail; the comprehensive pharmacokinetic record; the clinical evidence base across all studied indications; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event signal including the TMAO pathway; and a comparative assessment of five mitochondrial bioenergetic support compounds against L-carnitine on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1516Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026

←Previous Page

1 … 14 15 16 17 18 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.